Ticker	Volume	Price	Price Delta
DJIA	15,307.20	-80.41	-0.52%
S&P 500	1,655.35	-13.81	-0.83%
Nasdaq	3,463.30	-38.82	-1.11%

Ticker

Volume

Price

Price Delta

DJIA

15,307.20

-80.41

-0.52%

S&P 500

1,655.35

-13.81

-0.83%

Nasdaq

3,463.30

-38.82

-1.11%

Ticker	Volume	Price	Price Delta
STOXX 50	2,835.01	+13.36	0.47%
FTSE 100	6,840.27	+36.40	0.53%
DAX	8,530.89	+58.69	0.69%

Ticker

Volume

Price

Price Delta

STOXX 50

2,835.01

+13.36

0.47%

FTSE 100

6,840.27

+36.40

0.53%

DAX

8,530.89

+58.69

0.69%

Ticker	Volume	Price	Price Delta
Nikkei	15,663.00	+35.69	0.23%
Hang Seng	22,863.70	-397.35	-1.71%
S&P/ASX 200	5,072.00	-93.37	-1.81%

Ticker

Volume

Price

Price Delta

Nikkei

15,663.00

+35.69

0.23%

Hang Seng

22,863.70

-397.35

-1.71%

S&P/ASX 200

5,072.00

-93.37

-1.81%

Exchange: Stockholm
Sector: Consumer, Non-cyclical
Industry: Biotechnology
Sub-Industry: Agricultural Biotech

Probi AB

+ Add to Watchlist

PROB:SS

40.1000 SEK 1.9000 4.97%

Share this quote:

Post this quote on one of these sites:

Copy permanent URL

As of 11:30:07 ET on 05/22/2013.

Snapshot for Probi AB (PROB)

Open:	38.0000	Day's Range:	38.0000 - 40.6000	Volume:	53,802
Previous Close:	38.2000	52wk Range:	27.1000 - 66.7500	1-Yr Rtn:	-36.32%

Stock Chart for PROB

No chart data available.

PROB:SS 40.1000

38.2000

Interactive PROB Chart

…

Previous Close

Key Statistics for PROB

Current P/E Ratio (ttm)	30.5239
Estimated P/E(12/2013)	31.0853
Relative P/E vs. OMX	1.8640
Earnings Per Share (SEK) (ttm)	1.3137
Est. EPS (SEK) (12/2013)	1.2900
Est. PEG Ratio	-
Market Cap (M SEK)	375.55
Shares Outstanding (M)	9.37
30 Day Average Volume	7,888
Price/Book (mrq)	2.7834
Price/Sale (ttm)	3.8754
Dividend Indicated Gross Yield	1.87%
Cash Dividend (SEK)	0.7500
Last Dividend	04/25/2013
5 Year Dividend Growth	-
Next Earnings Announcement	08/16/2013

mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PROB

Revenue
Net Income (M/SEK)

Profit Margin (%)

Company Profile & Key Executives for PROB

Probi AB carries out research and development in probiotics. The Company has three main research areas: surgery and medicine, foodstuff technology, and microbiology. Probi has developed the fruit drink ProViva, containing active bioculture intended to counteract harmful bacteria and strengthen the immune system. The Company also develops animal feed. Probi markets internationally.